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The deposition of ﬁbrillated human islet b-cell peptide islet amyloid polypeptide (hIAPP) into amy-
loid plaques is characteristic of the pathogenesis of islet cell death during type 2 diabetes. We inves-
tigated the effects of the neuroendocrine secretory proteins 7B2 and proSAAS on hIAPP ﬁbrillation
in vitro and on cytotoxicity. In vitro, 21-kDa 7B2 and proSAAS blocked hIAPP ﬁbrillation. Structure–
function studies showed that a central region within 21-kDa 7B2 is important in this effect and
revealed the importance of the N-terminal region of proSAAS. Both chaperones blocked the cyto-
toxic effects of exogenous hIAPP on Rin5f cells; 7B2 generated by overexpression was also effective.
ProSAAS and 7B2 may perform a chaperone role as secretory anti-aggregants in normal islet cell
function and in type 2 diabetes.
Structured summary of protein interactions:
hIAPP and hIAPP bind by ﬂuorescence technology (View interaction)
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Amyloid formation plays a critical role in many different human
diseases, including Huntington’s disease (HD), Parkinson’s disease
(PD), Alzheimer’s disease (AD) and type 2 diabetes mellitus
(T2DM). Among these diseases, T2DM together with AD are leading
causes of morbidity and mortality in the elderly. Both diseases
share common clinical and biochemical features [1], including
functional tissue loss due to accumulation and aggregation of small
peptides, such as islet amyloid polypeptide in the pancreas of
T2DM patients, or beta amyloid in AD patients. Speciﬁcally, islet
amyloid polypeptide (IAPP) ﬁbrils arise following initial increased
production of IAPP which leads to oligomeric aggregation of IAPP
molecules that then assemble into amyloid ﬁbrils in pancreatic is-
lets, eventually resulting in pancreatic beta cell loss [2–4]. Beta cell
dysfunction leads to progressive impairment of insulin secretionand ultimately to overt T2DM [2]. Interestingly, only human IAPP
(hIAPP), but not rodent IAPP, forms oligomers and ﬁbrils [5], and
expression of hIAPP in rats causes formation of islet amyloid pla-
ques, loss of b-cells, and consequent diabetes [6].
IAAP is co-secreted with insulin from pancreatic b-cells [7].
Both IAPP and insulin are synthesized from larger precursors after
being proteolytically cleaved by PC1/3 and PC2 (prohormone con-
vertases 1/3 and 2) and carboxypeptidase E [8]. Both PC1/3 and PC2
have been shown to interact with speciﬁc binding proteins, proSA-
AS and 7B2, respectively; these proteins modulate convertase traf-
ﬁc through the secretory pathway, and, in the case of 7B2, perform
an important anti-aggregant function [9–11]. Abundant expression
of both convertases [12–14] and chaperones [15,16] has been dem-
onstrated in islet cells and studied in the context of diabetes and
function in glucagon and insulin synthesis. As the tissue distribu-
tions of 7B2 and proSAAS are much broader than those of the con-
vertases [17], additional functions are currently being investigated.
The recent discovery of 7B2 as a potent inhibitor of beta amyloid
and synuclein aggregation supports the idea that this family of
chaperones may serve as general secretory chaperones, acting to
prevent aggregation of proteins in AD and PD [18] and possibly
in other diseases which involve amyloid formation.
To investigate the potential inhibitory effect of 7B2 and proSA-
AS in preventing hIAPP ﬁbrillation, we have carried out an in vitro
ﬂuorescence-based ﬁbrillation study. We have also evaluated the
effect of both chaperones added extracellularly, in reducing the
J.R. Peinado et al. / FEBS Letters 587 (2013) 3406–3411 3407cytotoxicity of hIAPP in Rin5f insulinoma cells. Lastly, we have
tested the potential effect of intracellularly-expressed 7B2 and
proSAAS.
2. Materials and methods
2.1. Materials
Human IAPP (hIAPP) was purchased from Bachem and resus-
pended in DMSO at a concentration of 1 mM; 20 ll aliquots were
stored at 80 C and resuspended in 20 mM Tris–HCl, pH 7.5, to
a working concentration of 100 lM just before use.
2.2. Preparation of His-tagged 21-kDa 7B2 and 21-kDa proSAAS and
truncated proteins
Recombinant His-tagged 21-kDa 7B2 and 7B2 polypeptides
30–150 and 68–150 were prepared using the QIAexpress system
(Qiagen). Primers were designed as described previously [19].
PCR fragments were cloned into pQE30, and sequences were veri-
ﬁed by DNA sequencing. Proteins were expressed in Escherichia coli
XL1-Blue (Stratagene) and puriﬁed with the guanidine HCl/refold-
ing method as described previously [20]. Brieﬂy, bacterial overex-
pression was accomplished by IPTG induction and overnight
incubation of cultures at 26 C. Proteins were isolated via His-tag
chromatography and dialysis against phosphate–buffered saline.
21-kDa mouse His-tagged proSAAS (proSAAS 1–180) protein
was prepared as described previously [21]. ProSAAS138–180 and
proSAAS97–137 were synthesized at more than 85% purity at the
University of Maryland-Baltimore, Biopolymer Core Facility.
2.3. In vitro ﬁbrillation assays
hIAPP (10 lM ﬁnal concentration) was ﬁbrillated in 96-well
white Nunc polycarbonate plates [22] in 20 mM Tris–HCl buffer,
pH 7.4, in the presence or absence of either the 21-kDa 7B2 and
proSAAS proteins or peptides at the ﬁnal concentrations indicated
in the ﬁgures; carbonic anhydrase (CA) and insulin were used as
negative and positive controls, respectively. The reaction was car-
ried out in triplicate in a total volume of 100 ll at 25 C, and the
ﬁnal concentration of ThT was 20 lM; a Molecular Devices spec-
troﬂuorometer was used. Fibrillation was measured as an increase
in ThT ﬂuorescence (excitation wavelength 444 nm, emission
485 nm; [23]) upon binding to ﬁbrils. The data were then normal-
ized: the lowest ThT ﬂuorescence value detected was set at 0%
(time 0) and the highest ThT ﬂuorescence value for the assay was
set at 100%.
2.4. Cell culture and cytotoxicity assays
Rat insulinoma (Rin5f) cells were maintained in high glucose
DMEM and neuroblastoma (Neuro2A) cells in 50% DMEM and
50% Optimem. Both media were supplemented with 10% fetal
bovine serum (FBS; Atlanta Biologicals) and the cells cultured at
37 C in a humidiﬁed atmosphere containing 5% CO2. For cytotox-
icity assays Rin5f cells were plated in 96-well plates at a density of
about 50%. On the following day, cells were washed with
serum-free medium and treated with either vehicle, 21-kDa 7B2
(15 lM), 21-kDa proSAAS (15 lM), or carbonic anhydrase (5 lM)
as a negative control, for 48 h. Cell viability was measured using
the WST-1 cell proliferation reagent (Roche, Mannheim) and
absorption at 450 nm was measured every 30 min. The value for
vehicle-treated cells was set as 100%. Neuro2A cells were
transiently transfected with vectors encoding rat 21-kDa 7B2 and
mouse 27-kDa proSAAS for 24 h in a 96 well plate using theFuGENE-HD transfection reagent (Promega) as suggested by the
manufacturer. Cells were incubated for an additional 24 h in ser-
um-free media with 5 lM hIAPP before measuring cellular survival
rates. In one experiment, media and cells were collected for veriﬁ-
cation of chaperone expression in media and cells by Western
blotting.
2.5. Bioinformatics and statistical analysis
Prediction of a-helices in proSAAS was performed using the
GORIV and CFSSP programs through the Expasy server (expasy.org)
and also with PSIPRED (bioinf.cs.ucl.ac.uk). A tentative 3D proSAAS
model was made using BIOSERF based on the best-scoring hits
using PSI-BLAST, pGenTHREADER and HHPred at UCL-CS Bioinfor-
matics [24]. Potential disorder in proSAAS was investigated using
DISOPRED at UCL-CS Bioinformatics, and coiled–coils identiﬁed
by MARCOIL at the Expasy server. For statistical analysis, either
the Student’s unpaired t-test, or a one-way ANOVA followed by
Newman–Keuls multiple comparison was used to assess signiﬁ-
cance, as indicated in each ﬁgure; P-values with a value of
P < 0.05 were taken as statistically signiﬁcant.
3. Results
3.1. In vitro ﬁbrillation assay
We investigated hIAPP ﬁbrillation using an in vitro ﬂuorescence
assay using a ThT assay. In our hands, concentrations ranging from
5 to 20 lM of hIAPP exhibited complete ﬁbrillation within an hour
at 25 C and 10 lM was chosen for further assays (Fig. 1A). It has
been shown that ﬁbrillation of hIAPP is inhibited by insulin [25].
In our assays 5 lM insulin blocked 80% of hIAPP ﬁbrillation, while
an irrelevant control protein such as carbonic anhydrase did not
block ﬁbrillation (Fig. 1B). We also found that ﬁbrillation of hIAPP
was accelerated in the presence of salts, while detergents such as
Triton X-100 inhibited the reaction (data not shown); therefore,
the ﬁbrillation assays were carried out in a minimal salt-contain-
ing, detergent-free buffer.
3.2. 21-kDa 7B2 and proSAAS block hIAPP ﬁbrillation in vitro
Previous work in our laboratory has shown that the secretory
chaperone 7B2 not only colocalizes with amyloid plaques but also
inhibits beta amyloid ﬁbrillation [18]. Since 7B2 is abundant in the
pancreas [26] we investigated the possibility that 7B2 may also
inhibit hIAPP ﬁbrillation. We found 90% inhibition of hIAPP
ﬁbrillation with 10 lM 7B2, while 1 lM resulted in 50%
inhibition (Fig. 1C). ProSAAS is also abundant in the pancreas
[27]; in order to evaluate whether proSAAS also possesses
anti-ﬁbrillation ability, we carried out an assay using proSAAS
concentrations between 0.1 and 10 lM. Under these conditions
10 lM 21 kDa proSAAS blocked hIAPP ﬁbrillation completely and
0.1 lM still retained some inhibitory activity on ﬁbril formation
(Fig. 1D).
3.3. Residues 30–180 of 21-kDa 7B2 are sufﬁcient to block ﬁbrillation
of hIAAP
To elucidate the region within 7B2 responsible for the anti-
ﬁbrillation effect, we performed in vitro ﬁbrillation assays with
N-terminally truncated proteins. Structure–function analysis using
truncated forms of 7B2 revealed that the anti-aggregation effect
was greatest using 21-kDa 7B2 (Fig. 2A), although 10 lM
7B230–150 and 7B268–150 partially inhibited hIAPP ﬁbrillation by
30% and 20%, respectively (Fig. 2B).
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Fig. 1. Dose-dependence of 21-kDa 7B2 and 21-kDa proSAAS on hIAPP ﬁbrillation. Changes in ﬁbrillation kinetics according to hIAPP concentration 0–15 lM; (A). hIAPP was
also ﬁbrillated in the presence of a positive (insulin) and a negative (carbonic anhydrase, CA) control (B). Dose–dependent inhibition of hIAPP by 21-kDa 7B2 (C) and 21-kDa
proSAAS (D). Each ﬁbrillation data point represents the mean ± S.D., N = 3.
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Fig. 2. N-terminally truncated 7B2 proteins partially inhibit hIAPP ﬁbrillation.
Schematic diagram of 7B2 and the N-terminally truncated 7B2 constructs (A). hIAPP
(10 lM) was ﬁbrillated in the presence of vehicle or 10 lM of 7B2-2168–150 and
7B2-2130–150 constructs. The constructs block ﬁbrillation by 40% and 20%, respec-
tively (B). Each ﬁbrillation data point represents the mean ± S.D., N = 3. The C-
terminal peptide is indicated with a hatched square and the a-helices in gray
squares.
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of hIAAP ﬁbrillation
Bioinformatics research on the secondary structure of proSAAS
was performed as an attempt to identify potential structures re-
lated to its function as anti-aggregant. Various bioinformatics ap-
proaches (see Section 2) led us to identify three major regions
with alpha helical character, which lie between the disordered re-
gions predicted for proSAAS (Supplemental Fig. 1A). Interestingly,
these bioinformatics predictions identiﬁed a coiled–coil region
with higher than 93% probability scores (amino acids34–79; Supple-
mental Fig. 1B and C). The location of these identiﬁed alpha helices
in the 3D structure was performed by homology prediction, as
indicated in Section 2 (Supplemental Fig. 1D). According to this
prediction, two truncated peptides (Fig. 3A) were synthesized
(proSAAS97–137 and proSAAS138–180, see Section 2) to test whether
a-helices II and III play a role in proSAAS-induced inhibition of
ﬁbrillation. However, neither of these two peptides was able to in-
hibit ﬁbrillation in vitro (Fig. 3B). We conclude that residues 1–97
in the N-terminal domain contain key determinants for the anti-
ﬁbrillation ability of proSAAS on hIAPP.
3.5. 21-kDa 7B2 and 21-kDa proSAAS block hIAPP-mediated
cytotoxicity
Insoluble hIAPP amyloid aggregates colocalize with b cells, and
their formation is linked to the progressive deterioration of b cells
(reviewed in [28]). In addition, soluble hIAPP amyloid aggregates
have also been suggested to be cytotoxic [29,30]. Therefore, we
treated Rin5f insulinoma cells with recombinant 7B2 and proSAAS
to test whether they could exert cytoprotective effects against
LLP proSAAS 
138-180 
97-137  
ARP
DAP VYD 
DGP PAP
PAP
ARP
RRLRR 
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60
0
20
40
60
80
100 Cont
SAAS 97-137
SAAS 138-180
Time (min)
%
 F
ib
ril
la
tio
n
α-Helix I α-Helix II α-Helix III
21 kDa 
R RR Coiled-coil
A 
B 
Fig. 3. The a-helices II and III of proSAAS alone do not inhibit hIAPP ﬁbrillation.
Schematic diagram of proSAAS and the proSAAS-derived peptides (A). hIAPP
(10 lM) was ﬁbrillated in the presence of vehicle or 10 lM of the peptides (B). Each
ﬁbrillation data point represents the mean ± S.D., N = 3. The C-terminal peptide is
indicated with a hatched square and the a-helices in gray squares.
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tion used for the in vitro ﬁbrillation assays, resulted in less than
20% cell death, while 20 lM and higher doses resulted in complete
cell death (data not shown). We therefore chose a concentration of
15 lM hIAPP for our cytotoxicity assays, which resulted in approx-
imately 75% cell death (Fig. 4). Both 7B2 and proSAAS, at equimolar
concentrations to hIAPP, protected the cells from hIAPP-mediated
cytotoxicity. Incubation of the cells with both chaperones resulted
in less than 20% cell death, which is comparable with the resultsVe
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Fig. 4. Both 7B2 and proSAAS block hIAPP-induced cytotoxicity in Rin5f cells. Rin5f
cells were incubated for 24 h with 15 lM hIAPP in triplicate, resulting in 73%
cytotoxicity. The inclusion of 21-kDa proSAAS and 21-kDa 7B2 (in a 1:1 M ratio
with hIAPP) to the medium during the 24 h treatment signiﬁcantly blocked hIAPP-
mediated cell death, as assessed by WST-1 viability assay. Carbonic anhydrase and
insulin were added as negative and positive controls in an independent set of
hIAPP-treated Rin5f cells. Results represent the mean ± S.D., N = 3. ⁄⁄⁄P < 0.05.obtained with insulin (Fig. 4). To investigate whether toxicity
was due to ﬁbrillated or unﬁbrillated hIAPP we conducted an
in vitro ﬁbrillation assay that mimicked the conditions of the tox-
icity assay. We found that in the presence of Rin5f culture media
only a small percentage of the hIAPP was ﬁbrillated after 24 h
(Supplemental Fig. 2A), suggesting that ﬁbrils are not the cause
of hIAPP cytotoxicity.
3.6. Transfection of 7B2 cDNA into Neuro2A cells partially protects
cells from hIAPP toxicity
In order to evaluate the ability of intracellularly-expressed 7B2
and proSAAS to protect from hIAPP toxicity, we used neuroblas-
toma cells (Neuro2A), which express lower levels of endogenous
7B2 and a much higher transfection efﬁciency. Initial experiments
indicated that concentrations of hIAPP as low as 5 lM resulted in
strong cytotoxicity effect in this cell line (Fig. 5A and B). Transient
transfection of 7B2 cDNA, in which expression was conﬁrmed by
Western blotting of cell extracts and media (Supplemental
Fig. 2B), resulted in a signiﬁcant increase in cell proliferation when
compared to cells transfected with empty vector; similar effects
were not obtained using proSAAS cDNA. Interestingly, when the
7B2-transfected cells were examined under the microscope, they
did not show clear signs of apoptosis (Fig. 5A), indicating that
although the 7B2-transfected cells did not proliferate similarly to
the untreated cells, they were still viable.Em
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Fig. 5. Transfection of 7B2 cDNA increases cell survival after hIAPP treatment in
Neuro2A cells. Neuro2A cells were transfected with vectors encoding 7B2 and
proSAAS (24 h) and then incubated with 5 lM hIAPP (24 h). Most of the cells
transfected with the empty vector died after hIAPP treatment (A and B). Represen-
tative apoptotic cells are indicated with arrows. In contrast to proSAAS cDNA (A,
bottom left) transient transfection of 21-kDa 7b2 cDNA signiﬁcantly increased cell
survival after hIAPP treatment (B) and a reduced number of apoptotic cells was
observed (A, top right). ⁄P < 0.05; ⁄⁄P < 0.005.
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Increasing evidence indicates that the small proprotein conver-
tase binding proteins proSAAS and 7B2 are involved in chaperone
functions in neuroendocrine tissues. In addition to its role in block-
ing proPC2 aggregation [11,31], 7B2 also displays anti-aggregant
properties against neurodegeneration-related proteins such as b-
amyloid and a-synuclein [18]. Similar effects have been shown
for 7B2 in blocking the aggregation of insulin-like growth factor
1 (IGF1; [32]). Herein, we have demonstrated that added 7B2 can
block both in vitro ﬁbrillation of hIAPP and the cytotoxic effects
of hIAPP on Rin5f cells. The inhibition by 7B2 and its N-terminally
truncated proteins on hIAPP ﬁbrillation resembles the results ob-
served for inhibition of beta amyloid ﬁbrillation [18]; therefore,
we propose that 7B2 interferes with both Ab1-42 and hIAPP oligo-
merization via a similar molecular basis. This idea is also supported
by results showing a reduction in hIAPP cytotoxicity after 7B2
addition. It has been proposed that AD and non-insulin-dependent
T2DM may share a common mechanism of cell death which is re-
lated to the toxicity of beta amyloid and hIAPP oligomers, respec-
tively [33,34]. Type 2 diabetes constitutes a chronic metabolic
disorder that increases the risk for cerebrovascular disease and
for dementia [35,36]. Interestingly, although there is no evidence
of hIAPP synthesis in the brain, the presence of hIAPP oligomers
and plaques in the temporal lobe gray matter from diabetic pa-
tients has been recently identiﬁed [37]. 7B2 is abundant in both
brain and pancreatic islets, where it is likely co-secreted from neu-
rons together with beta amyloid and from beta cells together with
hIAPP, respectively. The inhibitory effect of 7B2 on hIAPP aggrega-
tion supports the idea that 7B2 may represent a defensive mecha-
nism against hIAPP deposition in vivo in type-2 derived amyloid
pathologies.
Since ﬁbrils do not form efﬁciently in Neuro2A cell medium,
7B2 may protect cells from hIAPP toxicity by blocking toxic oligo-
mer formation rather than by blocking ﬁbrillation. Alternatively, or
in addition, 7B2 may interfere with the interaction of hIAPP with
its receptor, thought to consist of a complex of the calcitonin
receptor coupled to a receptor modifying protein (reviewed in
[38]). The mechanism of chaperone cytoprotection deserves fur-
ther exploration.
In human diabetic pancreas of individuals suffering with b-cell
dysfunction and development of T2DM, hIAPP amyloid aggregates
are found exclusively extracellularly around islets (reviewed in
[28]), although studies on nude mice with transplanted human is-
lets [39] and in transgenic mice expressing hIAPP [40] have indi-
cated that the early stages of islet amyloid formation may take
place intracellularly. However, in our experiments, the primary ef-
fect of 7B2 in blocking cytotoxicity is likely to occur extracellularly,
as the majority of endogenous 7B2 is secreted by Neuro2A cells.
ProSAAS, a small neuroendocrine protein with structural resem-
blance to 7B2, also interacts with a convertase, PC1/3 [25], and
overexpression of this protein reduces its secretion [21]. Recent
ﬁndings indicate that proSAAS has a much broader distribution
pattern with respect to PC1/3 in the brain, and its abundance with-
in the pancreas has also been shown [16]. Furthermore, it has re-
cently been shown to constitute one of the most abundant
proteins within mature secretory granules in INS1-E insulinoma
cells [41]. These ﬁndings led us to hypothesize that proSAAS may
also perform additional functions in the pancreas. Herein, we have
demonstrated that proSAAS suppresses the ﬁbrillation of hIAPP
proteins in vitro while also protecting insulinoma cells from hIAPP
cytotoxicity when added extracellularly. Our structural analysis of
proSAAS revealed that the region between residues 35–80 consti-
tutes a potential coiled–coil, an idea which is in consonance with
homology modeling predictions indicating the possible existenceof an alpha helical structure in this region (Supplemental
Fig. 1D); such a helix is necessary for coiled–coil interactions. We
propose that this region may functionally interact with hIAPP, as
a-helices II and II alone do not inhibit ﬁbrillation. Interestingly,
in contrast to proSAAS, N-terminally truncated forms of 7B2 still
retained some inhibitory activity, and did not increase ﬁbrillation.
Previous studies have attempted to identify inhibitors of hIAPP
aggregation (i.e., resveratrol [42]), as well as endogenous secretory
proteins with anti-aggregation activity. The data presented here
show that the neuroendocrine chaperone proteins 7B2 and proSA-
AS, both expressed in beta cells, contain speciﬁc molecular features
which permit effective inhibition of hIAPP ﬁbrillation in vitro, and
toxicity in vivo. Understanding the molecular mechanisms of hIA-
PP–chaperone interaction will be an important step toward under-
standing hIAPP aggregation and cytotoxicity in the development of
type 2 diabetes.
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